Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
GeneDx shares leap 50% o n non-GAAP profitability GeneDx (NASDAQ: WGS) shares enjoyed another strong surge, leaping 50% from $56.06 to $84.02 Tuesday after the company announced encouraging third-quarter results that included the achievement of a non-GAAP profitability milestone
Dual GIP/GLP-1 agonists now represent the highest-revenue growth segment in the GLP-1 weight loss drug market at 18.4% CAGR , with tirzepatide generating USD 18.3 billion in 2025 revenue through Zepbound and Mounjaro surpassing Eli Lillys entire insulin franchise within two years of commercial launch
On Thursday, Janelle addressed the controversy and apologized if fans felt deceived by her confession
Reuters Health 2025.
An oversight here doesn't just compromise a sample
Reconstitute each compound independently
US$ 22.50
US$ 28.25
US$ 22.00
US$ 20.26
US$ 20.12
US$ 24.01
